Related to Curetis Obtains €24.5M to Support Commercialization of Diagnostics for Infectious Diseases

• IncellDx to Start U.S. Clinical Trials of HPV Test with $3M Financing
  
• DSM to Manufacture Novacta’s C. Difficile Compound for Preclinical and Phase I Studies
  
• BD Applies Exiqon Technology to Infectious Disease Diagnostics
  
• Skyline Diagnostics to Leverage TrovaGene NPM1 Technology in AML Diagnostic
  
• Palex Medical to Distribute MDI’s MRSA Diagnostic in Spain
  
• Asuragen and Life Technologies Launch BCR/ABL1 Quant Leukemia Test in Europe
  
• ELITech to Distribute Corgenix Diagnostics Outside North America with Initial $1.25M Investment
  
• FDA Green-Lights Thermo Fisher Scientific’s VRE Diagnostic
  
• New York State Licenses Genelex’ DNA Drug Sensitivity Tests
  
• FDA Gives Abbott a Thumbs-Up for Automated HBV Monitoring Test
  
• Novartis and Collaborators Discover Candidate for Drug-Resistant Malaria
  
• Qiagen and Abbott Forge Pact on Molecular Tests for HIV, HCV, and HPV
  
• MDI Announces Renaming Detect-Ready MRSA Screening Test and Distribution Agreement
  
• Life Technologies to Market PathoFinder Respiratory Pathogen ID Panels
  
• Biocartis Signs Assay Deal for Its MDx Platform with Janssen Pharmaceutica
  
• ExonHit Gets EC Clearance for Alzheimer Disease In Vitro Diagnostic
  
• Protagen Taps Scienion for Biomarker Panel Validation Work
  
• Roche’s Multivirus Blood-Screening Assay Achieves CE Mark
  
• Lab21 Takes Over Myconostica to Expand Portfolio of Diagnostics for Fungal Infections
  
• Qiagen Ups Bid for Cellestis by 7% with Eye on QuantiFERON Diagnostics Platform